B7H4/CD3 BsAb-oHSV-2

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameB7H4/CD3 BsAb-oHSV-2
Drug Alias NameN/A
ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-V-set domain-containing T-cell activation inhibitor 1Anti-CD3
TargetsV-set domain-containing T-cell activation inhibitor 1T cell surface glycoprotein CD3
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhongnan Hospital Of Wuhan UniversityHuazhong University Of Science And TechnologyHuazhong Agricultural University
China Registration ClassN/A

Develop Information

Active CompaniesZhongnan Hospital Of Wuhan UniversityHuazhong University Of Science And TechnologyHuazhong Agricultural University
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A